CCL11 and cancer: To predict the probability of 12-month survival in GBM patients, clinic-pathological characteristics including age, gender, family history of cancer, previous low-grade tumor, KPS, extent of surgery, diameter of tumor, and CCL11 and CCR3 immunostaining were included for leave-one-out cross-validation analysis.